COST-EFFECTIVENESS OF TREMELIMUMAB PLUS DURVALUMAB FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA IN THE UNITED STATES

被引：0
|
作者：
Xiong, X. [1 ]
Guo, J. J. [2 ]
机构：
[1] Univ Cincinnati, Cincinnati, OH USA
[2] Univ Cincinnati, Plain City, OH USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE520
引用
收藏
页码：S152 / S152
页数：1
相关论文
共 50 条
  • [31] Cost-Effectiveness of Nivolumab Plus Cabozantinib Versus Sunitinib as a First-Line Treatment for Advanced Renal Cell Carcinoma in the United States
    Li, SiNi
    Li, JianHe
    Peng, LiuBao
    Li, YaMin
    Wan, XiaoMin
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [32] Durvalumab receives second approval for the first-line treatment of advanced or unresectable hepatocellular carcinoma
    不详
    VISCERAL MEDICINE, 2024, 40 (01)
  • [33] Cost-Effectiveness Analysis of First-Line Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma in the United States
    Weiting Liao
    Wanting Lei
    Mingyang Feng
    Yang Yang
    Qiuji Wu
    Kexun Zhou
    Liangliang Bai
    Feng Wen
    Qiu Li
    Advances in Therapy, 2021, 38 : 5662 - 5670
  • [34] Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma
    Ye, Zhuo-miao
    Tang, Zi-Qing
    Xu, Zhe
    Zhou, Qin
    Li, Huan
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [35] Cost-Effectiveness Analysis of First-Line Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma in the United States
    Liao, Weiting
    Lei, Wanting
    Feng, Mingyang
    Yang, Yang
    Wu, Qiuji
    Zhou, Kexun
    Bai, Liangliang
    Wen, Feng
    Li, Qiu
    ADVANCES IN THERAPY, 2021, 38 (12) : 5662 - 5670
  • [36] Promising first-line immuno-combination therapies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis
    Wen, Feng
    Huang, Peng
    Wu, Qiuji
    Yang, Yang
    Zhou, Kexun
    Zhang, Mengxi
    Li, Qiu
    CANCER MEDICINE, 2024, 13 (16):
  • [37] First-Line Atezolizumab Plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
    Chiang, Chi-Leung
    Chan, Sik-Kwan
    Lee, Shing-Fung
    Choi, Horace Cheuk-Wai
    CANCERS, 2021, 13 (05) : 1 - 13
  • [38] First-line atezolizumab plus bevacizumab versus sorafenib in hepatocellular carcinoma: A cost-effectiveness analysis
    Chan, S.
    Chiang, C.
    Lee, S.
    Choi, H.
    ANNALS OF ONCOLOGY, 2021, 32 : S97 - S97
  • [39] Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States
    Aguiar-Ibanez, Raquel
    Hardern, Chloe
    van Hees, Frank
    Lee, Dawn
    Patel, Anubhav
    Chhabra, Nitika
    Baluni, Gargi
    Amonkar, Mayur
    Lai, Yizhen
    Xu, Ruifeng
    Massaad, Rachid
    Fogelman, David
    JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 469 - 480
  • [40] Efficacy of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma in immunotherapy era clinical practice
    Hiraoka, Atsushi
    Tada, Toshifumi
    Hirooka, Masashi
    Kariyama, Kazuya
    Tani, Joji
    Atsukawa, Masanori
    Takaguchi, Koichi
    Itobayashi, Ei
    Fukunishi, Shinya
    Tsuji, Kunihiko
    Ishikawa, Toru
    Tajiri, Kazuto
    Ohama, Hideko
    Toyoda, Hidenori
    Ogawa, Chikara
    Nishimura, Takashi
    Hatanaka, Takeshi
    Kakizaki, Satoru
    Kawata, Kazuhito
    Naganuma, Atsushi
    Kosaka, Hisashi
    Matono, Tomomitsu
    Kuroda, Hidekatsu
    Yata, Yutaka
    Nishikawa, Hiroki
    Imai, Michitaka
    Aoki, Tomoko
    Ochi, Hironori
    Tada, Fujimasa
    Nakamura, Shinichiro
    Nakamura, Yoshiko
    Nouso, Kazuhiro
    Morishita, Asahiro
    Itokawa, Norio
    Okubo, Tomomi
    Arai, Taeang
    Tsutsui, Akemi
    Nagano, Takuya
    Tanaka, Kazunari
    Tanaka, Hironori
    Koshiyama, Yuichi
    Kanayama, Yuki
    Noritake, Hidenao
    Enomoto, Hirayuki
    Kaibori, Masaki
    Hiasa, Yoichi
    Kudo, Masatoshi
    Kumada, Takashi
    HEPATOLOGY RESEARCH, 2025, 55 (03) : 444 - 453
12345